Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe
Femasys (NASDAQ: FEMY) announced an initial commercial order of approximately $500,000 to launch FemBloc Permanent Birth Control in France and the Benelux region through distributor Kebomed, dated Nov 10, 2025. This follows the company’s recent entry into Spain and represents continued European expansion for the non-surgical permanent contraceptive.
FemBloc is described as a first‑of‑its‑kind, non‑surgical permanent contraception that places a proprietary polymer into both fallopian tubes to form permanent occlusion without anesthesia, incisions, or recovery time, positioning the product as a potentially disruptive global offering.
Femasys (NASDAQ: FEMY) ha annunciato un primo ordine commerciale di circa $500,000 per lanciare FemBloc Permanent Birth Control in Francia e nella regione Benelux tramite il distributore Kebomed, datato 10 novembre 2025. Questo segue l’ingresso recente dell’azienda in Spagna e rappresenta una continua espansione europea per il contraccettivo permanente non chirurgico.
FemBloc è descritto come un metodo anticoncezionale permanente non chirurgico, unico nel suo genere, che introduce una polimerizzazione proprietaria in entrambe le tube di Falloppio per formare un'occlusione permanente senza anestesia, incisioni o tempo di recupero, posizionando il prodotto come un'offerta globale potenzialmente dirompente.
Femasys (NASDAQ: FEMY) anunció un pedido comercial inicial de aproximadamente $500,000 para lanzar FemBloc Permanent Birth Control en Francia y la región Benelux a través del distribuidor Kebomed, fechado el 10 de noviembre de 2025. Esto sigue a la reciente entrada de la empresa en España y representa una expansión continua en Europa para el anticonceptivo permanente no quirúrgico.
FemBloc se describe como un anticonceptivo permanente no quirúrgico, de su tipo, que coloca un polímero propietario en ambas trompas de Falopio para formar una oclusión permanente sin anestesia, incisiones ni tiempo de recuperación, posicionando el producto como una oferta global potencialmente disruptiva.
Femasys (NASDAQ: FEMY)는 Kebomed 유통사를 통해 프랑스와 벤루지역에서 FemBloc 영구 피임을 런칭하기 위한 약 $500,000의 초기 상업 주문을 발표했습니다. 날짜는 2025년 11월 10일입니다. 이는 회사의 최근 스페인 진출에 이어 유럽 전역으로의 지속적인 확장을 나타내는 비수술적 영구 피임법입니다.
FemBloc은 고유한 중합체(polymer)를 양쪽 난관에 삽입하여 마취, 절개, 회복 시간 없이 영구 폐쇄를 형성하는 일종의 비수술적 영구 피임법으로 설명되며, 제품을 전 세계에 잠재적으로 파괴적인 제공으로 포지셔닝합니다.
Femasys (NASDAQ: FEMY) a annoncé une commande commerciale initiale d’environ $500,000 pour lancer FemBloc Permanent Birth Control en France et la région Benelux via le distributeur Kebomed, datée du 10 novembre 2025. Cela fait suite à l’entrée récente de l’entreprise en Espagne et représente une expansion européenne continue pour ce contraceptif permanent non chirurgical.
FemBloc est décrit comme un moyen de contraception permanent non chirurgical, unique en son genre, qui place un polymère propriétaire dans les deux trompes de Fallope pour former une occlusion permanente sans anesthésie, ni incisions, ni temps de récupération, positionnant le produit comme une offre mondiale potentiellement révolutionnaire.
Femasys (NASDAQ: FEMY) kündigte eine erste kommerzielle Bestellung von ca. $500,000 an, um FemBloc Permanent Birth Control in Frankreich und der Benelux-Region über den Distributor Kebomed einzuführen, datiert auf 10. November 2025. Dies folgt dem jüngsten Eintritt der Firma in Spanien und repräsentiert eine anhaltende europäische Expansion des nicht-chirurgischen Persistenz-Verhütungsmittel.
FemBloc wird als erstmaliges, nicht-chirurgisches dauerhaftes Verhütungsmittel beschrieben, das einen proprietären Polymer in beide Eileiter einführt, um eine permanente Occlusion zu bilden, ohne Anästhesie, Einschnitte oder Erholungszeit, und positioniert das Produkt als potenziell disruptives internationales Angebot.
فيماسيس (روابط التداول: فيمي) أعلنت عن أمر تجاري أولي بحدود $500,000 لإطلاق FemBloc Permanent Birth Control في فرنسا ومنطقة بنيلكس من خلال الموزع Kebomed، بتاريخ 10 نوفمبر 2025. يتبع ذلك دخول الشركة الأخير إلى إسبانيا ويمثل توسعًا أوروبيًا مستمرًا للوسيلة الواقية الدائمة غير الجراحية.
يُوصف FemBloc بأنه وسيلة منع حمل دائمة غير جراحية من نوعها الأولى، تضع بوليمرًا مملوكًا في كلا قناتي فالوب لتكوين انسداد دائم دون تخدير، ولا شقوق، ولا وقت تعافٍ، مما يضع المنتج كمقترح عالمي قد يكون ثوريًا.
- Initial order of approximately $500,000 for France and Benelux
- Commercial launch follows entry into Spain, signaling regional rollout
- Non-surgical permanent solution with no anesthesia or incisions
- Initial commercial order is limited to France and Benelux (~$500,000)
- Announcement discloses one initial order without recurring revenue details
Insights
Initial €/$500k partner order signals commercial rollout momentum in Europe, validating distribution strategy.
Femasys booked an initial commercial order of approximately
The business impact depends on consistent execution by distribution partners and on converting reported end‑market demand into sustained sales; the announcement itself confirms demand perception from both women and physicians and a commercial channel capable of placing inventory. Key items to watch over the next 6–12 months include order fulfillment and replenishment cadence, additional partner rollouts or repeat orders, and early adoption signals from clinicians and patients in the launched markets.
-- Continued rollout of FemBloc, the breakthrough non-surgical permanent contraceptive solution, expands the Company’s presence in key European Markets --
ATLANTA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, today announced a significant initial order valued at approximately
“Our selection of European partners, such as Kebomed, has been deliberate and strategic, ensuring both deep expertise in market access and a shared commitment to advancing women’s healthcare,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “The initial orders reflect confidence in FemBloc’s potential to transform reproductive health. With these partnerships driving our international expansion, Femasys is well positioned to create lasting impact for patients and long-term value for shareholders.”
"We are pleased to partner with Femasys to bring FemBloc to women in France and Benelux," said Søren Dalmark Kornerup, Chairman of Kebomed Europe AG. "For several years, there has been a void in permanent contraception options, with no new advancements to meet the clear demand from both women and physicians. FemBloc represents a revolutionary breakthrough that the market has been waiting for, and we are thrilled to be at the forefront of introducing this much-needed solution."
FemBloc is a first-of-its-kind, non-surgical solution for permanent birth control, addressing a significant unmet need in women’s reproductive health. It uses a patented delivery system to place a proprietary blended polymer into both fallopian tubes, which safely degrades and forms natural scar tissue for permanent occlusion. Unlike surgical sterilization, FemBloc requires no anesthesia, no incisions, and no recovery time, avoiding the risks of infection and other surgical complications while providing women a safer, more convenient, and affordable option. With no comparable alternatives on the market, FemBloc represents a disruptive advancement with broad global potential. Learn more at www.FemBloc.com.
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
About Kebomed
Kebomed Europe AG is a leading independent distributor of medical devices with more than 30 years of heritage and a strong footprint across Europe. Founded in 1995 in Scandinavia, the company expanded through acquisitions in the UK, Benelux, Norway, followed by France, Switzerland, Germany, and Austria, establishing itself as one of the few truly pan-European platforms. Women’s health has long been a strategic focus for Kebomed, supported by its close relationship with LiNA Medical, an innovator in minimally invasive gynecology owned by the same family. Through this connection, Kebomed distributes LiNA products in select European markets, strengthening its portfolio and reinforcing its leadership and deep clinical expertise in this important therapeutic area. More information on Kebomed can be found at www.kebomed.com.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ
What did Femasys (FEMY) announce on Nov 10, 2025?
How large is the FemBloc order tied to Femasys (FEMY) European launch?
Which markets will Femasys expand into with the Kebomed partnership for FemBloc?
What makes FemBloc different from surgical sterilization according to Femasys (FEMY)?
Does the Nov 10, 2025 announcement say FemBloc is already in other European markets?
